In a report published Wednesday, Jefferies analyst Omotayo Okusanya reiterated a Buy rating on Biomed Realty Trust BMR, and slightly raised the price target from $24.00 to $25.00.
In the report, Okusanya noted, “Management teams expressed confidence in the ability to grow internally as well as externally via accretive acquisitions and development. The outlook for Medicare and Medicaid reimbursement seems benign over the next 12 months which is a positive. In our view, the biggest challenge is valuation, although several names seem set for better than expected FFO/sh growth in 2013.”
Biomed Realty Trust closed on Tuesday at $21.56.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in